Infectious Disease Therapeutics Market by Drug Class (Antibiotics, Antifungals, Antivirals), Route Of Administration (Inhalation, Intravenous, Oral), Indication, End User, Distribution Channel - Global Forecast 2025-2032
Description
The Infectious Disease Therapeutics Market was valued at USD 121.27 billion in 2024 and is projected to grow to USD 126.80 billion in 2025, with a CAGR of 5.28%, reaching USD 183.13 billion by 2032.
Executive overview framing the contemporary infectious disease therapeutics landscape, strategic priorities, and emergent imperatives for healthcare decision-makers
This executive summary introduces a synthesis of contemporary developments shaping infectious disease therapeutics, framed to support evidence-driven decision-making across clinical, commercial, and policy functions.
The opening analysis situates recent scientific advances alongside evolving regulatory expectations and persistent supply chain complexities. It emphasizes the convergence of novel therapeutic modalities, adaptive clinical trial designs, and heightened health system expectations for rapid, equitable access. Moreover, the introduction underscores how these forces are driving new partnership architectures between developers, providers, and payers. By establishing this context, readers are prepared to evaluate subsequent sections that interrogate disruptive trends, segmentation-specific dynamics, regional nuances, corporate strategy, and actionable recommendations for leaders seeking to build resilient and patient-centered portfolios.
Throughout, the prose prioritizes clarity and practical relevance. Transitional commentary highlights where short-term operational pressures intersect with longer-term strategic choices, enabling readers to quickly identify priority topics for executive attention. The introduction therefore functions both as a roadmap to the report and as an initial framing device that aligns clinical imperatives with commercial viability and public health impact.
Identification of transformative shifts reshaping infectious disease therapeutics through scientific innovation, regulatory evolution, and supply chain realignment
Transformative shifts in infectious disease therapeutics are occurring across science, delivery, and policy, producing a new operating reality for developers and health systems alike.
On the scientific front, advances in biologics and vaccine platforms are expanding the therapeutic toolkit beyond small molecules, while precision-targeted approaches are improving therapeutic indices and clinical outcomes. Concurrently, digital health tools and real-world evidence platforms are accelerating patient identification, trial enrollment, and post-approval surveillance, thereby compressing the time from discovery to clinical validation. These technical shifts are mirrored by evolving regulatory paradigms that emphasize accelerated pathways, adaptive licensing, and lifecycle evidence generation; as a result, stakeholders must recalibrate development timelines and evidence strategies to meet both regulator and payer expectations.
Supply chain resilience has emerged as a strategic priority, with manufacturers reassessing sourcing, inventory, and distribution models to mitigate disruption. Meanwhile, payer and procurement systems are increasingly focused on value-based contracting and outcome-linked reimbursement, which demand robust, longitudinal evidence of clinical and economic benefit. Collectively, these trends are reshaping competitive dynamics, investment priorities, and partnership structures, prompting organizations to be more agile in portfolio management while deepening collaborations with clinical and public health stakeholders.
Assessment of cumulative effects of United States tariffs enacted in 2025 on supply chain resilience, procurement strategy, and commercial operations within therapeutics
The 2025 tariffs implemented by the United States have introduced layered effects across supply chains, procurement strategies, and commercial behaviors within the infectious disease therapeutics ecosystem.
Initially, manufacturers and distributors experienced immediate increases in input costs and transportation overhead, prompting a review of sourcing footprints and contractual terms. In turn, procurement teams and hospital systems began prioritizing suppliers with geographically diversified or localized manufacturing to reduce exposure, while some developers accelerated onshoring initiatives to protect critical component availability. As a consequence, strategic sourcing evolved from a cost-only calculus to a resilience-first approach, where lead times, dual-sourcing options, and supplier financial health became equally important metrics in supplier selection.
Over time, organizations adapted by optimizing production schedules, investing in inventory buffers for critical inputs, and renegotiating long-term supply agreements that included resilience clauses. Payers and health systems also responded by intensifying price transparency efforts and by evaluating total cost of care implications associated with procurement strategy shifts. These cumulative adjustments have reinforced the need for end-to-end visibility across procurement, manufacturing, and distribution, and they have elevated cross-functional collaboration between commercial, regulatory, and operations teams to mitigate tariff-driven volatility and preserve continuity of care.
Granular segmentation insights revealing therapeutic class differentiation, administration route implications, clinical indications, distribution channels, and end-user dynamics driving strategy
A granular segmentation lens reveals differentiated dynamics that must inform portfolio prioritization, clinical development sequencing, and channel strategies. Based on drug class, the therapeutic landscape spans conventional small-molecule antibiotics, antifungals, and antivirals, as well as advanced biologics and multiple vaccine platforms; within antibiotics, distinctions among aminoglycosides, beta-lactams, fluoroquinolones, macrolides, and tetracyclines highlight divergent resistance profiles and stewardship priorities, while antifungals categorized as azoles, echinocandins, and polyenes reflect varying toxicity and administration trade-offs. Antiviral subclasses such as integrase inhibitors, neuraminidase inhibitors, nucleoside analogues, and protease inhibitors show distinct mechanism-of-action considerations that influence combination therapy design and resistance monitoring. Biologics differentiated into cytokines and monoclonal antibodies present unique manufacturing and regulatory demands, and vaccines segmented into conjugate, inactivated, live attenuated, and subunit types demand discrete cold-chain, deployment, and public acceptance strategies.
In parallel, route of administration influences clinical adoption and adherence, with inhalation, intravenous, oral, and topical options each driving different clinical workflows and patient support requirements. Indication-focused segmentation across COVID-19, gastrointestinal infections, hepatitis, HIV/AIDS, respiratory infections, skin infections, and urinary tract infections underscores variable clinical trial endpoints, public health prioritization, and payer expectations. Distribution channel differentiation among hospital pharmacy, online pharmacy, and retail pharmacy dictates fulfillment logistics and point-of-care interfacing, while end-user segmentation among clinics, homecare, and hospitals affects demand forecasting and service models. Taken together, these intersecting segmentation axes create a mosaic of opportunities and constraints; as a result, strategy must be tailored to the clinical profile, distribution realities, and end-user operational capabilities associated with each segment.
Regional intelligence highlighting divergent trends, manufacturing capacity considerations, regulatory complexity, and investment priorities across major global regions
Regional dynamics exhibit pronounced heterogeneity, with each geography presenting unique demand drivers, regulatory environments, and infrastructure considerations that shape therapeutic strategies. In the Americas, there is a persistent focus on rapid innovation adoption, integrated payer-provider contracting, and heightened scrutiny on clinical and economic outcomes, which together foster an environment that rewards differentiated value propositions and scalable commercialization models. By contrast, Europe, Middle East & Africa presents a complex landscape marked by diverse regulatory frameworks, variable public health capacity, and regional procurement mechanisms that require tailored market access approaches and flexible pricing strategies to ensure broad uptake.
Meanwhile, the Asia-Pacific region demonstrates pronounced manufacturing capacity, growing clinical trial activity, and rising investment in local innovation ecosystems, which collectively create opportunities for strategic partnerships and regional manufacturing hubs. These geographic contrasts imply that companies must deploy region-specific playbooks that account for varying approval pathways, distribution networks, and payer expectations. Moreover, transitional initiatives such as harmonized regulatory requirements and regional procurement collaborations are emerging, which organizations should monitor closely as potential enablers of cross-border scale. In conclusion, regional intelligence should inform not only where to invest but also how to adapt evidence generation, pricing, and distribution to the realities of each jurisdiction.
Competitive intelligence synthesizing corporate strategies, partnership models, pipeline differentiation, and operational choices that shape competitive advantage in therapeutics
Competitive dynamics are driven by an interplay of research intensity, manufacturing capabilities, and strategic partnerships that define how companies capture clinical leadership and commercial footholds. Leading organizations are differentiating through targeted pipeline investments in high-priority indications, deliberate expansion of biologics and vaccine capabilities, and the cultivation of integrated service offerings that combine therapeutic development with diagnostics and digital patient support. Furthermore, strategic alliances between developers, contract manufacturers, and specialty distributors have become common, allowing companies to accelerate time-to-clinic and to de-risk manufacturing scale-up while preserving capital efficiency.
In addition, corporate strategies increasingly emphasize lifecycle management, combination therapy development, and real-world evidence generation as mechanisms to sustain product value and to negotiate favorable access terms with payers. Mergers and acquisitions remain an active lever for accessing complementary technologies, regional footprints, or specialized manufacturing capacity. Equally important, mid-sized and emerging entrants are leveraging niche expertise and agile development models to challenge incumbents in targeted indications. Thus, competitive advantage is increasingly contingent on an organization’s ability to integrate scientific excellence with operational scale and to deploy flexible commercial models that respond to payer and provider expectations.
Practical and forward-looking recommendations for industry leaders to strengthen resilience, accelerate innovation, and translate therapeutic advances into sustainable commercial value
Industry leaders should pursue a set of pragmatic, forward-looking actions that align scientific opportunity with operational resilience and commercial viability. First, organizations must prioritize portfolio rationalization that favors programs with clear clinical differentiation and feasible delivery pathways, while simultaneously investing in platform capabilities for biologics and vaccines that support long-term competitiveness. Second, building supply chain resilience through diversified sourcing, strategic onshoring where feasible, and collaborative contracts with key suppliers will reduce exposure to geopolitical and tariff-related shocks and support steady clinical supply.
Third, evidence strategies should be redesigned to incorporate adaptive trial designs, real-world evidence, and health economics data to satisfy regulators and payers while shortening time-to-decision. Fourth, commercialization models must become more flexible, integrating digital engagement, specialty distribution partners, and outcomes-linked contracting to meet diverse payer and provider needs. Fifth, leaders should cultivate strategic partnerships across academia, contract manufacturing, and digital health providers to accelerate innovation and to share risk. Finally, organizational governance must support cross-functional decision-making, ensuring that clinical, regulatory, commercial, and operations teams align on go/no-go criteria and resource allocation. Collectively, these actions will strengthen an organization’s capacity to deliver patient-centered therapies at scale and to respond to evolving external pressures.
Transparent research methodology detailing data sources, expert engagement, analytical frameworks, and quality controls that support the study's findings
The research methodology underpinning the report combines multiple evidence streams, expert engagement, and structured analytical frameworks to ensure robust and transparent conclusions. Primary research included structured interviews with clinical investigators, supply chain executives, payers, and regulatory experts to capture operational realities and stakeholder priorities. Secondary research consisted of systematic review of peer-reviewed literature, regulatory guidance, and publicly disclosed clinical trial registries, which provided contextual validation for thematic findings and technology assessments.
Analytical methods integrated qualitative synthesis with scenario-based stress testing to evaluate operational vulnerabilities and strategic options. Cross-validation steps involved triangulating interview insights with documented regulatory actions and published clinical outcomes to reduce bias and to enhance confidence in interpretation. Quality controls included codebook-driven thematic analysis, multi-reviewer validation, and selective external peer review of key assumptions. Finally, ethical and confidentiality standards were observed throughout primary research engagements, with respondents contributing insights under agreed nondisclosure terms. Together, these methodological safeguards ensure that the report’s conclusions are actionable, reproducible, and aligned with stakeholder needs.
Concise synthesis of strategic implications, priority actions, and the need for coordinated stakeholder approaches to advance infectious disease therapeutics
The conclusion synthesizes strategic implications and reaffirms the imperative for coordinated action across stakeholders to realize the potential of infectious disease therapeutics. Key strategic imperatives include aligning development priorities with unmet clinical needs, reinforcing supply chain and manufacturing resilience, and generating the types of evidence that payers and providers require for broad adoption. Equally, the ecosystem must embrace cross-sector collaboration-uniting developers, health systems, and public health authorities-to ensure that innovation translates into equitable access and measurable health impact.
In the near term, organizations that integrate adaptive clinical designs, robust real-world evidence programs, and flexible commercialization models will be best positioned to capture clinical leadership and to sustain product value. Over the longer term, sustained investment in platform technologies and regional manufacturing capacity will strengthen resilience and foster innovation ecosystems capable of responding to emerging threats. Ultimately, the path forward combines strategic focus with operational discipline, enabling stakeholders to deliver therapeutics that improve patient outcomes while navigating an increasingly complex global environment.
Note: PDF & Excel + Online Access - 1 Year
Executive overview framing the contemporary infectious disease therapeutics landscape, strategic priorities, and emergent imperatives for healthcare decision-makers
This executive summary introduces a synthesis of contemporary developments shaping infectious disease therapeutics, framed to support evidence-driven decision-making across clinical, commercial, and policy functions.
The opening analysis situates recent scientific advances alongside evolving regulatory expectations and persistent supply chain complexities. It emphasizes the convergence of novel therapeutic modalities, adaptive clinical trial designs, and heightened health system expectations for rapid, equitable access. Moreover, the introduction underscores how these forces are driving new partnership architectures between developers, providers, and payers. By establishing this context, readers are prepared to evaluate subsequent sections that interrogate disruptive trends, segmentation-specific dynamics, regional nuances, corporate strategy, and actionable recommendations for leaders seeking to build resilient and patient-centered portfolios.
Throughout, the prose prioritizes clarity and practical relevance. Transitional commentary highlights where short-term operational pressures intersect with longer-term strategic choices, enabling readers to quickly identify priority topics for executive attention. The introduction therefore functions both as a roadmap to the report and as an initial framing device that aligns clinical imperatives with commercial viability and public health impact.
Identification of transformative shifts reshaping infectious disease therapeutics through scientific innovation, regulatory evolution, and supply chain realignment
Transformative shifts in infectious disease therapeutics are occurring across science, delivery, and policy, producing a new operating reality for developers and health systems alike.
On the scientific front, advances in biologics and vaccine platforms are expanding the therapeutic toolkit beyond small molecules, while precision-targeted approaches are improving therapeutic indices and clinical outcomes. Concurrently, digital health tools and real-world evidence platforms are accelerating patient identification, trial enrollment, and post-approval surveillance, thereby compressing the time from discovery to clinical validation. These technical shifts are mirrored by evolving regulatory paradigms that emphasize accelerated pathways, adaptive licensing, and lifecycle evidence generation; as a result, stakeholders must recalibrate development timelines and evidence strategies to meet both regulator and payer expectations.
Supply chain resilience has emerged as a strategic priority, with manufacturers reassessing sourcing, inventory, and distribution models to mitigate disruption. Meanwhile, payer and procurement systems are increasingly focused on value-based contracting and outcome-linked reimbursement, which demand robust, longitudinal evidence of clinical and economic benefit. Collectively, these trends are reshaping competitive dynamics, investment priorities, and partnership structures, prompting organizations to be more agile in portfolio management while deepening collaborations with clinical and public health stakeholders.
Assessment of cumulative effects of United States tariffs enacted in 2025 on supply chain resilience, procurement strategy, and commercial operations within therapeutics
The 2025 tariffs implemented by the United States have introduced layered effects across supply chains, procurement strategies, and commercial behaviors within the infectious disease therapeutics ecosystem.
Initially, manufacturers and distributors experienced immediate increases in input costs and transportation overhead, prompting a review of sourcing footprints and contractual terms. In turn, procurement teams and hospital systems began prioritizing suppliers with geographically diversified or localized manufacturing to reduce exposure, while some developers accelerated onshoring initiatives to protect critical component availability. As a consequence, strategic sourcing evolved from a cost-only calculus to a resilience-first approach, where lead times, dual-sourcing options, and supplier financial health became equally important metrics in supplier selection.
Over time, organizations adapted by optimizing production schedules, investing in inventory buffers for critical inputs, and renegotiating long-term supply agreements that included resilience clauses. Payers and health systems also responded by intensifying price transparency efforts and by evaluating total cost of care implications associated with procurement strategy shifts. These cumulative adjustments have reinforced the need for end-to-end visibility across procurement, manufacturing, and distribution, and they have elevated cross-functional collaboration between commercial, regulatory, and operations teams to mitigate tariff-driven volatility and preserve continuity of care.
Granular segmentation insights revealing therapeutic class differentiation, administration route implications, clinical indications, distribution channels, and end-user dynamics driving strategy
A granular segmentation lens reveals differentiated dynamics that must inform portfolio prioritization, clinical development sequencing, and channel strategies. Based on drug class, the therapeutic landscape spans conventional small-molecule antibiotics, antifungals, and antivirals, as well as advanced biologics and multiple vaccine platforms; within antibiotics, distinctions among aminoglycosides, beta-lactams, fluoroquinolones, macrolides, and tetracyclines highlight divergent resistance profiles and stewardship priorities, while antifungals categorized as azoles, echinocandins, and polyenes reflect varying toxicity and administration trade-offs. Antiviral subclasses such as integrase inhibitors, neuraminidase inhibitors, nucleoside analogues, and protease inhibitors show distinct mechanism-of-action considerations that influence combination therapy design and resistance monitoring. Biologics differentiated into cytokines and monoclonal antibodies present unique manufacturing and regulatory demands, and vaccines segmented into conjugate, inactivated, live attenuated, and subunit types demand discrete cold-chain, deployment, and public acceptance strategies.
In parallel, route of administration influences clinical adoption and adherence, with inhalation, intravenous, oral, and topical options each driving different clinical workflows and patient support requirements. Indication-focused segmentation across COVID-19, gastrointestinal infections, hepatitis, HIV/AIDS, respiratory infections, skin infections, and urinary tract infections underscores variable clinical trial endpoints, public health prioritization, and payer expectations. Distribution channel differentiation among hospital pharmacy, online pharmacy, and retail pharmacy dictates fulfillment logistics and point-of-care interfacing, while end-user segmentation among clinics, homecare, and hospitals affects demand forecasting and service models. Taken together, these intersecting segmentation axes create a mosaic of opportunities and constraints; as a result, strategy must be tailored to the clinical profile, distribution realities, and end-user operational capabilities associated with each segment.
Regional intelligence highlighting divergent trends, manufacturing capacity considerations, regulatory complexity, and investment priorities across major global regions
Regional dynamics exhibit pronounced heterogeneity, with each geography presenting unique demand drivers, regulatory environments, and infrastructure considerations that shape therapeutic strategies. In the Americas, there is a persistent focus on rapid innovation adoption, integrated payer-provider contracting, and heightened scrutiny on clinical and economic outcomes, which together foster an environment that rewards differentiated value propositions and scalable commercialization models. By contrast, Europe, Middle East & Africa presents a complex landscape marked by diverse regulatory frameworks, variable public health capacity, and regional procurement mechanisms that require tailored market access approaches and flexible pricing strategies to ensure broad uptake.
Meanwhile, the Asia-Pacific region demonstrates pronounced manufacturing capacity, growing clinical trial activity, and rising investment in local innovation ecosystems, which collectively create opportunities for strategic partnerships and regional manufacturing hubs. These geographic contrasts imply that companies must deploy region-specific playbooks that account for varying approval pathways, distribution networks, and payer expectations. Moreover, transitional initiatives such as harmonized regulatory requirements and regional procurement collaborations are emerging, which organizations should monitor closely as potential enablers of cross-border scale. In conclusion, regional intelligence should inform not only where to invest but also how to adapt evidence generation, pricing, and distribution to the realities of each jurisdiction.
Competitive intelligence synthesizing corporate strategies, partnership models, pipeline differentiation, and operational choices that shape competitive advantage in therapeutics
Competitive dynamics are driven by an interplay of research intensity, manufacturing capabilities, and strategic partnerships that define how companies capture clinical leadership and commercial footholds. Leading organizations are differentiating through targeted pipeline investments in high-priority indications, deliberate expansion of biologics and vaccine capabilities, and the cultivation of integrated service offerings that combine therapeutic development with diagnostics and digital patient support. Furthermore, strategic alliances between developers, contract manufacturers, and specialty distributors have become common, allowing companies to accelerate time-to-clinic and to de-risk manufacturing scale-up while preserving capital efficiency.
In addition, corporate strategies increasingly emphasize lifecycle management, combination therapy development, and real-world evidence generation as mechanisms to sustain product value and to negotiate favorable access terms with payers. Mergers and acquisitions remain an active lever for accessing complementary technologies, regional footprints, or specialized manufacturing capacity. Equally important, mid-sized and emerging entrants are leveraging niche expertise and agile development models to challenge incumbents in targeted indications. Thus, competitive advantage is increasingly contingent on an organization’s ability to integrate scientific excellence with operational scale and to deploy flexible commercial models that respond to payer and provider expectations.
Practical and forward-looking recommendations for industry leaders to strengthen resilience, accelerate innovation, and translate therapeutic advances into sustainable commercial value
Industry leaders should pursue a set of pragmatic, forward-looking actions that align scientific opportunity with operational resilience and commercial viability. First, organizations must prioritize portfolio rationalization that favors programs with clear clinical differentiation and feasible delivery pathways, while simultaneously investing in platform capabilities for biologics and vaccines that support long-term competitiveness. Second, building supply chain resilience through diversified sourcing, strategic onshoring where feasible, and collaborative contracts with key suppliers will reduce exposure to geopolitical and tariff-related shocks and support steady clinical supply.
Third, evidence strategies should be redesigned to incorporate adaptive trial designs, real-world evidence, and health economics data to satisfy regulators and payers while shortening time-to-decision. Fourth, commercialization models must become more flexible, integrating digital engagement, specialty distribution partners, and outcomes-linked contracting to meet diverse payer and provider needs. Fifth, leaders should cultivate strategic partnerships across academia, contract manufacturing, and digital health providers to accelerate innovation and to share risk. Finally, organizational governance must support cross-functional decision-making, ensuring that clinical, regulatory, commercial, and operations teams align on go/no-go criteria and resource allocation. Collectively, these actions will strengthen an organization’s capacity to deliver patient-centered therapies at scale and to respond to evolving external pressures.
Transparent research methodology detailing data sources, expert engagement, analytical frameworks, and quality controls that support the study's findings
The research methodology underpinning the report combines multiple evidence streams, expert engagement, and structured analytical frameworks to ensure robust and transparent conclusions. Primary research included structured interviews with clinical investigators, supply chain executives, payers, and regulatory experts to capture operational realities and stakeholder priorities. Secondary research consisted of systematic review of peer-reviewed literature, regulatory guidance, and publicly disclosed clinical trial registries, which provided contextual validation for thematic findings and technology assessments.
Analytical methods integrated qualitative synthesis with scenario-based stress testing to evaluate operational vulnerabilities and strategic options. Cross-validation steps involved triangulating interview insights with documented regulatory actions and published clinical outcomes to reduce bias and to enhance confidence in interpretation. Quality controls included codebook-driven thematic analysis, multi-reviewer validation, and selective external peer review of key assumptions. Finally, ethical and confidentiality standards were observed throughout primary research engagements, with respondents contributing insights under agreed nondisclosure terms. Together, these methodological safeguards ensure that the report’s conclusions are actionable, reproducible, and aligned with stakeholder needs.
Concise synthesis of strategic implications, priority actions, and the need for coordinated stakeholder approaches to advance infectious disease therapeutics
The conclusion synthesizes strategic implications and reaffirms the imperative for coordinated action across stakeholders to realize the potential of infectious disease therapeutics. Key strategic imperatives include aligning development priorities with unmet clinical needs, reinforcing supply chain and manufacturing resilience, and generating the types of evidence that payers and providers require for broad adoption. Equally, the ecosystem must embrace cross-sector collaboration-uniting developers, health systems, and public health authorities-to ensure that innovation translates into equitable access and measurable health impact.
In the near term, organizations that integrate adaptive clinical designs, robust real-world evidence programs, and flexible commercialization models will be best positioned to capture clinical leadership and to sustain product value. Over the longer term, sustained investment in platform technologies and regional manufacturing capacity will strengthen resilience and foster innovation ecosystems capable of responding to emerging threats. Ultimately, the path forward combines strategic focus with operational discipline, enabling stakeholders to deliver therapeutics that improve patient outcomes while navigating an increasingly complex global environment.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
188 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Accelerated development of mRNA-based vaccines for seasonal and emerging respiratory virus prevention
- 5.2. Increased adoption of long-acting monoclonal antibodies for prophylaxis in immunocompromised COVID-19 patients
- 5.3. Integration of CRISPR-based rapid diagnostics with bespoke antibiotic stewardship in tertiary care hospitals
- 5.4. Clinical advancement of broad-spectrum viral polymerase inhibitors for pandemic respiratory pathogen readiness
- 5.5. Emergence of oral direct-acting antivirals targeting hepatitis delta co-infection in chronic hepatitis B regimes
- 5.6. Innovation in host-directed therapies aiming to modulate innate immunity and reduce sepsis-related mortality
- 5.7. Engineering synthetic antimicrobial peptides to overcome multidrug-resistant bacterial infections in clinical trials
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Infectious Disease Therapeutics Market, by Drug Class
- 8.1. Antibiotics
- 8.1.1. Aminoglycosides
- 8.1.2. Beta Lactams
- 8.1.3. Fluoroquinolones
- 8.1.4. Macrolides
- 8.1.5. Tetracyclines
- 8.2. Antifungals
- 8.2.1. Azoles
- 8.2.2. Echinocandins
- 8.2.3. Polyenes
- 8.3. Antivirals
- 8.3.1. Integrase Inhibitors
- 8.3.2. Neuraminidase Inhibitors
- 8.3.3. Nucleoside Analogues
- 8.3.4. Protease Inhibitors
- 8.4. Biologics
- 8.4.1. Cytokines
- 8.4.2. Monoclonal Antibodies
- 8.5. Vaccines
- 8.5.1. Conjugate
- 8.5.2. Inactivated
- 8.5.3. Live Attenuated
- 8.5.4. Subunit
- 9. Infectious Disease Therapeutics Market, by Route Of Administration
- 9.1. Inhalation
- 9.2. Intravenous
- 9.3. Oral
- 9.4. Topical
- 10. Infectious Disease Therapeutics Market, by Indication
- 10.1. COVID-19
- 10.2. Gastrointestinal Infections
- 10.3. Hepatitis
- 10.4. HIV/AIDS
- 10.5. Respiratory Infections
- 10.6. Skin Infections
- 10.7. Urinary Tract Infections
- 11. Infectious Disease Therapeutics Market, by End User
- 11.1. Clinics
- 11.2. Homecare
- 11.3. Hospitals
- 12. Infectious Disease Therapeutics Market, by Distribution Channel
- 12.1. Hospital Pharmacy
- 12.2. Online Pharmacy
- 12.3. Retail Pharmacy
- 13. Infectious Disease Therapeutics Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Infectious Disease Therapeutics Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Infectious Disease Therapeutics Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. AbbVie Inc.
- 16.3.2. Alexion Pharmaceuticals, Inc.
- 16.3.3. Allergan PLC
- 16.3.4. Amgen Inc.
- 16.3.5. Astellas Pharma US, Inc.
- 16.3.6. AstraZeneca PLC
- 16.3.7. Bayer AG
- 16.3.8. BioCryst Pharmaceuticals, Inc.
- 16.3.9. Biogen Inc.
- 16.3.10. Boehringer Ingelheim GmbH
- 16.3.11. Bristol-Myers Squibb Company
- 16.3.12. Celgene Corporation
- 16.3.13. Chimerix, Inc.
- 16.3.14. Eli Lilly and Company
- 16.3.15. Gilead Sciences, Inc.
- 16.3.16. GlaxoSmithKline PLC
- 16.3.17. Johnson & Johnson Services, Inc.
- 16.3.18. Merck & Co., Inc.
- 16.3.19. Mitsubishi Chemical Group Corporation
- 16.3.20. Mylan N.V.
- 16.3.21. Novartis AG
- 16.3.22. Novo Nordisk A/S
- 16.3.23. Pfizer Inc.
- 16.3.24. Sanofi S.A.
- 16.3.25. Takeda Pharmaceutical Co. Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
